NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
about
Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineProspects for developing an effective particle-mediated DNA vaccine against influenza.Preclinical and clinical development of DNA vaccines for prostate cancer.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Immunologic response to xenogeneic gp100 DNA in melanoma patients: comparison of particle-mediated epidermal delivery with intramuscular injection.DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer.Human prostate tumor antigen-specific CD8+ regulatory T cells are inhibited by CTLA-4 or IL-35 blockadeCancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications.Therapeutic cancer vaccines: are we there yet?Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review.Immunological milieu in the peritoneal cavity at laparotomy for gastric cancerPhase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancerDNA vaccines, electroporation and their applications in cancer treatmentMultiple vaccinations: friend or foe.Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissuesMechanisms of T-cell inhibition: implications for cancer immunotherapy.Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination.The Five Immune Forces Impacting DNA-Based Cancer Immunotherapeutic Strategy.Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1.Prostate cancer vaccines in clinical trials.New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Monitoring regulatory immune responses in tumor immunotherapy clinical trials.Immunotherapy in prostate cancer: review of the current evidence.Selection of epitopes from self-antigens for eliciting Th2 or Th1 activity in the treatment of autoimmune disease or cancer.Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes.DNA vaccines for prostate cancer.DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1.Current Strategies to Enhance Anti-Tumour Immunity.Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma
P2860
Q28483146-7BAAE288-F59A-4E42-B051-2A4BBEA04AA3Q30380300-C19EA499-A254-4F3D-BE12-3C3BF9FB258FQ33740811-583D702F-ADCD-4EC8-8B01-E1712DE6148BQ33994533-F8CA0BD7-563F-44B2-AE49-79417E037E88Q34325790-EF66FA55-54EF-4569-B43F-7E07258B7D81Q34508125-9226FE50-7B87-4603-9E4E-04379897ADEBQ34561877-6672553B-C18F-4FE6-9F19-64192EC18B8CQ34610121-B6C68E3F-6DC9-49BA-9383-5B00EF985EA5Q34645401-7B8D1574-5E2A-4FD2-A152-5A4EF3CCD6BEQ34753747-B5230947-4980-42D7-8EF5-AEEA80C4B473Q34786691-D079790F-8D6B-4EBB-BA1A-DBDEEA4759EBQ34898280-71DD50A7-3FD1-4CBE-A575-C52F446D8C91Q34993621-61BF6031-6AA0-4D07-89A1-0428BFAC6277Q35872049-E8BBB049-BA2F-4A2F-BF71-2D2701BDA045Q35951653-8343816B-08D3-437C-A3A5-663BA28DB674Q36256459-ACA77640-DAE5-4901-A36C-B7C424CEC067Q36734688-0672DEB8-CDF3-49C8-826E-28EAFD10EBD6Q37017023-851B5A89-425F-4CAF-B10F-FFDB2FA96A26Q37115223-FE4DB0F0-2B91-4C4E-849C-8C6CFE493CB3Q37658886-94C28211-E0C3-40A9-AE52-A7B8E6860332Q37703163-D7A319C5-77DA-44BD-8506-C3347FDAFE2DQ37729321-3136379D-1E35-46C7-B6C6-9E434E1A1A37Q37762274-DA3B3862-FECD-45B5-9FBB-A9E7D1AEC2D6Q38036690-A2EEF738-D25B-4FEC-9BC2-66F413ED4A29Q38089480-2D9F1586-0846-48C6-B67C-E24912E62607Q38105081-7511B7E8-781C-4768-A641-EEDF5F585319Q38283918-0CDC5A27-93F9-457E-A485-83510A7C81ADQ39038768-46F66C56-79B1-4D5D-A286-B48725CAB2D7Q50912428-B014D2DA-5E8D-4E62-8D4D-E3613EA0DBD2Q51142505-7A0C39DD-E284-45F9-9AE1-EDEC08CFEDDCQ51825111-3A15A38E-951A-4CF1-8A9F-699AE896E988Q52344613-91860DC4-AA15-4EB1-976D-31BBBF5D7A6BQ57571845-5ABBE322-76C9-48C1-9073-98264E55FDA2
P2860
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@en
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@nl
type
label
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@en
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@nl
prefLabel
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@en
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@nl
P2093
P2860
P1476
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.
@en
P2093
Christopher J Logothetis
Derek Ng Tang
Gerd Ritter
Lloyd J Old
Nasser K Altorki
Padmanee Sharma
Sacha Gnjatic
Shi-Ming Tu
Vikas Kundra
P2860
P304
P356
10.1158/1078-0432.CCR-08-2632
P407
P577
2009-03-10T00:00:00Z